Innovative Biologics

Innovative biologics are advanced medicines that offer targeted therapy for cancer, autoimmune diseases, or rare diseases, among others. The biologics market is growing rapidly. It is shaped by precision medicine and complex therapeutic formats.

We see innovative biologics as a platform spans monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates, and recombinant therapeutic proteins. Across those modalities, the common foundation is the same: robust cell lines, precise analytics, disciplined control of critical quality attributes, and cGMP execution from gene to vial.

Mabion’s vision is to be the most flexible and technologically advanced large-molecule CDMO for biologics in Europe. That ambition is grounded in public evidence: Mabion already emphasizes high-quality biological products, integrated process development, and a long-term partner model across the biologics lifecycle.

Monoclonal Antibodies

• Drug Substance Manufacturing
• Drug Characterization
• Process Development
• Cell Line Development

Monoclonal antibodies are one of the most established and commercially important classes of innovative biologics, combining precise target recognition with proven therapeutic value across oncology, autoimmune diseases, inflammation, respiratory disorders, and emerging cardiovascular indications. With global demand for antibody-based therapies continuing to grow, Mabion supports monoclonal antibody development and GMP manufacturing through a platform designed for quality, flexibility, and scientific precision. Building on our experience with complex antibody molecules, Mabion helps transform lead target biology into robust large-molecule drug substance processes.

Learn more about our Monoclonal Antibodies services.

Bispecific Antibodies

Bispecific antibodies are engineered to bind two targets, epitopes, or cell types at the same time. That dual-target structure allows these innovative biologics to do more than a conventional monoclonal antibody. They can redirect T cells toward cancer cells, block two disease pathways simultaneously, or combine tumor recognition with immune activation. This makes them especially relevant in oncology, hematologic malignancies, solid tumors, and immune-mediated diseases where target biology is complex and multi-pathway intervention may improve clinical potential.

Learn more about our Bispecific Antibodies services.

Multispecific Antibodies

Multispecifics are best described as next-generation therapeutics designed to engage more than two targets or mechanisms in one molecule. Leading benchmark companies frame them as tools for tackling complex disease biology, particularly when one pathway is not enough to generate a durable clinical effect. That makes them especially relevant in oncology, immunology, and other diseases shaped by redundancy or heterogeneous target expression.

Learn more about our Multispecific Antibodies services.

Antibody-Drug Conjugates

Antibody-drug conjugates combine the selectivity of an antibody with the potency of a cytotoxic payload, joined through a linker that controls stability and release. They are often described as biological missiles because the targeting component directs a highly active payload toward cells that express the relevant antigen. ADCs are a powerful tool in targeted therapy, where therapeutic success depends on precise target selection and controlled payload release.

Mabion delivers ADC development and manufacturing programs through a consortium partner model. In this area, we operate under a master provider model. This enables the entire project to be carried out under a single umbrella agreement, ensuring the innovator receives optimal collaboration conditions while maintaining high-quality services.

Learn more about our Antibody-drug conjugates services.